News

EpitoGenesis was awarded a Phase I Advanced Technology STTR grant from the National Institutes of Allergy and Infectious Diseases to

EpitoGenesis enters into an agreement with Children’s Hospital Oakland Research Institute on a collaborative project to develop a vaccine against

EpitoGenesis, Inc. is awarded an NIH grant to further explore the NIDS technology for HIV vaccines.

EpitoGenesis begins collaboration with Dr. Julia Hurwitz at St. Jude’s Hospital on an HIV vaccine project and submission of a

EpitoGenesis Publication: Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes.Yu M, Vajdy M.Expert Opin Biol Ther.

EpitoGenesis acquired preclinical results in murine models demonstrating that the proprietary nutritive immune-enhancing delivery system (NIDS) significantly enhanced immune responses

EpitoGenesis acquired preclinical results in murine models demonstrating that the proprietary nutritive immune-enhancing delivery system (NIDS) significantly enhanced immune responses

EpitoGenesis Inc. was awarded a Phase I, Small Business Innovation Research grant from the National Institutes of Health to develop

EpitoGenesis Inc. filed an application for an SBIR phase I grant for research and development of a mucosal HIV vaccine.

Moved in Laboratory and office space at 112 La Casa Via, suite 160, Walnut Creek, California, across from John Muir